Đánh giá hiệu quả điều trị ung thư biểu mô buồng trứng giai đoạn III-IV bằng phác đồ Paclitaxel-Carboplatin kết hợp Bevacizumab tại Bệnh viện Hữu Nghị Việt Tiệp=Evaluate results of treatment for stage III-IV epithelial ovarian cancer with the regimen Paclitaxel-Carboplatin combined with Bevacizumab at Viet Tiep Hospital

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Thị Phương Thảo Nguyễn, Thị Quy Nguyễn, Thị Thanh Hoa Nguyễn, Văn Sang Phạm

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Tạp chí Y học Việt Nam (Tổng hội Y học Việt Nam), 2024

Mô tả vật lý: tr.496-502

Bộ sưu tập: Báo, Tạp chí

ID: 245871

Thêm vào giỏ

Đánh giá một số đặc điểm lâm sàng, cận lâm sàng và hiệu quả điều trị của bệnh nhân ung thư biểu mô tế buồng trứng giai đoạn III - IV được điều trị bằng phác đồ Paclitaxel-Carboplatin kết hợp Bevacizumab. - Phương pháp: Nghiên cứu mô tả hồi cứu, đối tượng nghiên cứu là 18 bệnh nhân ung thư biểu mô buồng trứng (UTBMBT) giai đoạn III - IV được điều trị bằng phác đồ Paclitaxel-Carboplatin kết hợp Bevacizumab tại bệnh viện Hữu Nghị Việt Tiệp từ tháng 1/2022 đến tháng 12/2023. - Kết quả: Tuổi trung bình của nhóm bệnh nhân nghiên cứu là 56 tuổi, phần lớn vào viện vì đau bụng với chỉ số toàn trạng tốt (ECOG 0-1 chiếm 88,9%). Nồng độ CA12-5 rất cao ở đa số các trường hợp, với thể mô bệnh học carcinoma thanh dịch chiếm đa số. Giai đoạn III chiếm phần lớn trong nhóm nghiên cứu (77,8%). Thời gian sống bệnh không tiến triển đạt 15,2 ± 1,2 tháng. Trung vị thời gian sống thêm liên quan có ý nghĩa thống kê với giai đoạn bệnh. Độc tính hay gặp chủ yếu độ I-II. - Kết luận: Phác đồ Paclitaxel-Carboplatin kết hợp Bevacizumab mang lại hiệu quả cao trong điều trị bệnh nhân UTBMBT giai đoạn III-IV với độc tính dung nạp được.Evaluation of some clinial and paraclinical characteristics of patients with stage III-IV epithelial ovarian cancer treated with the paclitaxel-carboplatin regimen combined with Bevacizuamb Method: This is a descriptive study. The study subjects were 18 patients with stage III-IV epithelial ovarian cancer (EOC) treated with the paclitaxel-carboplatin regimen combined with Bevacizuamb at Viet Tiep Hospital from January 2022 to December 2023. Results: The average age of patients is 56 years old, most of them present abdomen pain with good performance status (ECOG 0-1 for 88,9% cases). The CA 125 concentration is markedly elevated in most case, with the histological subtype of serous carcinoma is majority.Stage III accounts for majority within study group. The progression-free survival time reaches 15,2 ±1,2 months. Median of the progression-free survival time is statistically significant associatin with stage. Common toxicities are mainly grade 1-2. Conclusion: The paclitaxel-carboplatin regimen combined with Bevacizuamb demonstrates high effectiveness and good tolerability in treating patients with stage III-IV epithelial ovarian cancer

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR